This week Mark and Amy dig into KPV, a tiny fragment of the hormone α-MSH, and the lab research on its anti-inflammatory effects in gut cells and mice. They also look at two new 2026 lab papers, how to weigh personal reports, and why "not FDA-approved" is not a verdict either way.
What we covered
- What KPV is: the last three amino acids (lysine, proline, valine) of α-MSH
- The site's evidence level of 2 out of 5: cell and mouse colitis studies, no published human trials
- How KPV is described as entering gut-lining and immune cells via PepT1 and dampening NF-κB and MAP-kinase pathways
- Why its gut effect does not appear to run through melanocortin receptors, so it is not a tanning peptide
- A 2026 Tissue & Cell study in mouse macrophages showing similar pathway effects (abstract only, one cell line, nothing about colitis)
- A 2026 Tissue & Cell fat-cell paper, with oral KPV in mice on a high-fat diet
- How to weigh "calmer gut and skin" reports: real, but anecdotal
- Why FDA status is one signal among several, and a note that KPV is on the WADA banned list
Sources
- https://www.mypeps.info/blog/kpv-gut-inflammation-research
- https://www.mypeps.info/methodology
- Lysine-Proline-Valine attenuates oxidized low-density lipoprotein-induced foam cell formation and inflammatory responses in RAW264.7 macrophages, Tissue & Cell, Oct 2026: https://pubmed.ncbi.nlm.nih.gov/42854645/
- Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards, International Journal of Pharmaceutical Compounding, Sep 2026: https://pubmed.ncbi.nlm.nih.gov/42752426/
- KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signaling, Tissue & Cell, Aug 2026: https://pubmed.ncbi.nlm.nih.gov/42585803/
Free tools
- Peptide calculator: https://www.mypeps.info/calculator
This is education, not medical advice.
Educational information, not medical advice. Mark and Amy are AI-generated voices; every episode is reviewed by our editor, Ryan E., MS.